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SUMMARY. The reason(s) that hepatitis A virus (HAV)
infection may progress infrequently to acute liver failure are
poorly understood. We examined host and viral factors in 29
consecutive adult patients with HAV-associated acute liver
failure enrolled at 10 sites participating in the US ALF Study
Group. Eighteen of twenty-four acute liver failure sera were
PCR positive while six had no detectable virus. HAV geno-
type was determined using phylogenetic analysis and the
full-length genome sequences of the HAV from a cute liver
failure sera were compared to those from self-limited acute
HAV cases selected from the CDC database. We found that
rates of nucleotide substitution did not vary significantly
between the liver failure and non-liver failure cases and
there was no significant variation in amino acid sequences
between the two groups. Four of 18 HAV isolates were sub-
genotype IB, acquired from the same study site over a 3.5-
year period. Sub-genotype IB was found more frequently
among acute liver failure cases compared to the non-liver
failure cases (chi-square test, P < 0.01). At another centre, a
mother and her son presented with HAV and liver failure
within 1 month of each other. Predictors of spontaneous
survival included detectable serum HAV RNA, while age,
gender, HAV genotype and nucleotide substitutions were not
associated with outcome. The more frequent appearance of
rapid viral clearance and its association with poor outcomes
in acute liver failure as well as the finding of familial cases
imply a possible host genetic predisposition that contributes
to a fulminant course. Recurrent cases of the rare sub-
genotype IB over several years at a single centre imply a
community reservoir of infection and possible increased
pathogenicity of certain infrequent viral genotypes.
Keywords: acute liver failure, epidemiology, genome sequenc-
ing, hepatitis A.
INTRODUCTION
Hepatitis A virus (HAV), a single stranded RNA virus, is
endemic throughout most of the world and is also highly
genetically conserved [1,2]. In the United States, rates of
infection have dropped significantly with increased use of the
hepatitis A vaccine, however the estimated incidence is still
above 30 000 new infections per year [3]. The infection
usually follows an innocuous course, remaining sub-clinical
in most children, while appearing as acute self-limited hep-
atitis in adults. Less than 1% of acute hepatitis A cases result
in acute liver failure [4,5]. HAV infection currently accounts
for only 3% of adult acute liver failure (ALF) cases in the
United States [4,6]. Although hepatitis A-related ALF
patients experience a relatively high spontaneous survival
rate (69%), the remaining patients either die or require
emergency liver transplantation [7].
The relationship between self-limited hepatitis A cases and
those HAV infections resulting in ALF (HAV ALF) is poorly
understood. Host factors including age and underlying liver
disease are thought to increase the likelihood of a fulminant
course [8,9]. Viral factors including low viral load and a
higher rate of substitution in the 5¢ untranslated region
(UTR) of the viral RNA have also been correlated with
increased frequency of HAV-related ALF [10,11]. Another
potential viral factor is genotype. Epidemiologic studies in
the United States have demonstrated that sub-genotype IA
is most common, comprising 98% of infections, while
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sub-genotype IB is found in only 2%; most IB infections have
been associated with international travel [12]. To date, no
correlation between ALF and HAV genotype has been evi-
dent but this has not been systematically examined. Previous
studies have focused on the 5¢ UTR and VP1-P2B regions,
while only small case series have evaluated the entire HAV
genome of HAV ALF cases [13]. This study aimed to further
explore both host and viral factors, including genotype and
nucleotide sequence variation in the entire HAV genome
among consecutive adult cases of HAV ALF from the mul-
ticentre adult US acute liver failure registry. To identify
factors contributing to variation in outcomes, full genome
sequences of 18 HAV ALF cases were compared to geo-
graphically matched controls: patients with self-limited
acute HAV identified in the CDC database.
PATIENTS AND METHODS
The adult US Acute Liver Failure Study Group (ALFSG) is a
cooperative effort of 23 tertiary liver centres to study the
aetiology and outcomes of ALF [14]. Twenty-nine patients
from the ALFSG registry were diagnosed with HAV ALF
between January 1998 and May 2004 and all of these
patients were included in this study. ALF was defined as the
onset of encephalopathy and coagulopathy within 26 weeks
of first symptoms of hepatic illness with no prior history of
liver disease [15]. Encephalopathy was defined as any degree
of altered mentation while coagulopathy was defined by an
international normalized ratio (INR) ‡1.5. ALF was attrib-
uted to acute HAV infection when a positive IgM anti-HAV
antibody test was obtained in conjunction with consistent
clinical findings by the site investigator and the data-coor-
dinating centre. All patients tested negative for other
markers of acute viral infection including HBsAg, anti-HBc
IgM, anti-HCV with the exception of two patients. One had
typical acute HAV infection but was hepatitis C virus (HCV)
antibody positive without detectable HCV RNA on repeated
testing, unlikely to represent acute hepatitis C. One patient
had evidence of both chronic hepatitis B and C with
detectable HBsAg, anti-HCV, HBV DNA and HCV RNA
detected but was shown to be anti-HAV IgM positive and
recovered fully from ALF.
Informed consent, approved by the Institutional Review
Board of each of the respective centres, was obtained from
the next of kin due to the patients altered mental status and
all cases were coded to maintain anonymity. Detailed data
including the patients demographics, history, laboratory
results, and outcome were obtained. Sera were collected
daily for up to 7 days, stored at )80 C and shipped to the
central repository for continued storage prior to testing.
A series of randomly selected sera from US and Mexican
patients with acute hepatitis A infection in the CDC database
was used as controls for the HAV whole-genome analysis.
These control sera included 20 sub-genotype IA and 8 sub-
genotype IB specimens obtained over a similar time frame
from a comparable US geographic distribution as the HAV
ALF cases.
HAV RNA amplification and sequencing
Serum samples (collected on day 1 or no later than day 4)
were available from 24 of 29 patients. These samples were
used for HAV whole-genome amplification. HAV surveil-
lance databases at the Division of Viral Hepatitis, Centers for
Disease Control and Prevention, Atlanta, GA, USA were
accessed to form a demographically comparable control
group of acute hepatitis cases for comparison of the entire
viral RNA genome. RNA was extracted using the Total
Nucleic Acid Isolation kit in conjunction with a MagNAPure
LC system (Roche Applied Science, Indianapolis, IN, USA).
Extracted RNA was used as a template in a one step RT-PCR
reaction (QIAGEN, Valencia, CA, USA) to amplify 14
different overlapping fragments encompassing the entire
length of the HAV genome. Nested PCR was carried out for
each amplicon to generate fragments suitable for sequenc-
ing. Sequencing of both DNA strands was carried out with
the corresponding internal primers using BigDye v3.1
chemistry (Applied Biosystems, Foster City, CA, USA). The
resulting products from the sequencing reaction were
cleaned using the Millipore Montage SEQ96 Cleanup Kit
(Millipore, Billerica, MA, USA) and later run on 3130xl
Genetic Analyzer (Applied Biosystems). All reactions were
performed on a Biomek 3000 Laboratory Automation
Workstation (Beckman Coulter, Fullerton, CA, USA).
Sequences were assembled and preliminarily analysed using
SeqMan and MegAlign programs from the Lasergene DNA &
Protein analysis package v8.0.2 (DNASTAR Inc., Madison,
WI, USA) The Accelrys GCG Package v11.0 (Accelrys Inc.
San Diego, CA, USA) was used for phylogenetic analysis.
Shannon entropy was expressed as mean + standard devi-
ation (SD). Differences in Shannon entropy and viral genetic
identity were tested by ANOVA. SAS for Windows version
9.2 (SAS Institute Inc., Cary, NC, USA) was used for
statistics analysis.
Measurement of acetaminophen protein adducts
Adducts in sera were measured using a high-performance
liquid chromatography method with electrochemical detec-
tion as previously described [16,17].
RESULTS
Epidemiological data
The 29 patients were obtained from 10 of the 23 ALFSG
sites; demographic and laboratory data are shown in
Table 1. Four patients with sub-genotype IB were from the
same site (site 23, University of Michigan) and presented
over the course of 3.5 years. That same site demonstrated
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one sub-genotype IA case during the study period as well.
Site 35, Albert Einstein Medical College, recorded two
related HAV ALF patients admitted within 1 month of each
other, a mother and son. The mothers infection preceded
the sons. Although they did not live together they had
shared meals during the mothers period of infection. There
were no other known interactions between patients or
common risk factors other than geographic location and
none of the patients had migrated from an endemic area
outside of the United States.
Patient outcomes
Sixteen of twenty-nine (55%) patients recovered spontane-
ously (e.g. without transplantation). Nine of twenty-nine
(31%) received a liver transplant and eight survived at least
3 weeks post transplant. Four of twenty-nine patients (14%)
died from renal failure, brain oedema, respiratory failure or
cardiac arrest.
HAV genetic analyses
Eighteen of twenty-four (75%) samples were RT-PCR
positive (Table 1). To confirm the PCR negative results, we
repeated testing on later (day 3) samples. Five of the six
remained negative. The entire genome of 15 of the 18 ini-
tially PCR positive cases was sequenced. Within the three
cases that could not be completely sequenced; the VP1-P2B
(nt 2912–3277) region and 5¢ UTR were sequenced suc-
cessfully. Based on phylogenetic analysis of the VP1-P2B
region 14 cases were classified as sub-genotype IA and 4
cases as sub-genotype IB. The complete HAV-genome
sequences of the 15 ALF cases were compared with a control
group of sequences of sub-genotype IA (n = 20) and sub-
genotype IB (n = 8) retrieved from the CDC surveillance
databases of acute hepatitis A cases (Fig. 1). The nucleotide
and amino acid sequences were compared between ALF
cases and controls within the same sub-genotype. There
were no apparent sequence differences or specific nucleotide/
Table 1 Demographic and clinical data for 29 patients with HAV-related acute liver failure
No. Gender Age APAP use Adducts Serum PCR Status Genotype Peak ALT Peak AST Outcome
1 Male 23 ) <LLQ + + 1A 2946 331 SS
2 Male 52 ) N/A ) N/A N/A 364 262 LTx
3 Female 32 + N/A + + 1A 3333 3212 SS
4 Male 72 ) N/A ) N/A N/A 1214 2340 LTx
5 Female 21 + <LLQ + ) 1A 2664 1039 SS
6 Male 55 + <LLQ + ) 1A 170 204 Died
7 Female 39 + 0.238 + + 1A 607 763 SS
8 Male 47 + <LLQ + ) 1A 2404 892 LTx
9 Male 41 ) <LLQ + ) 1A 1516 4000 LTx
10 Female 60 ) <LLQ + + 1A 7560 1353 LTx
11 Male 48 ) <LLQ + + 1A 4134 924 SS
12 Female 72 ) N/A ) N/A N/A 3266 1235 SS
13 Female 41 ) <LLQ + ) 1A 947 2241 LTx
14 Female 57 ) <LLQ + + 1A 4914 4784 SS
15 Male 57 ) N/A ) N/A N/A 3147 896 LTx
16 Male 64 ) N/A ) N/A N/A 3052 5470 Died
17 Male 40 ) <LLQ + ) 1A 1898 3346* LTx & Died
18 Male 55 ) <LLQ + + 1A 1659 2157* LTx
19 Female 46 + <LLQ + + 1B 6591 5993 SS
20 Male 21 ) <LLQ + + 1B 3440 2384 SS
21 Female 66 ) <LLQ + + 1B 2102 734 Died
22 Male 32 ) < LLQ + + 1B 9817 >9000 SS
23 Female 57 + 0.18 + + 1A 2622 623 SS
24 Female 45 + 0.338 + + 1A 1367 330 SS
25 Male 50 + 0.279 + + 1A 2658 583 Died
26 Female 53 + <LLQ + + 1A 2482 607 SS
27 Female 43 + <LLQ + + 1A 1989 2486 SS
28 Female 69 + <LLQ + + 1A 4440 2069 SS
29 Male 44 ) <LLQ + + 1A 6795 4417 SS
SS, spontaneous survival; <LLQ, below lower limit quantification.
*Anti-HCV positive.
Concomitant chronic HBV/HCV.
 2010 Blackwell Publishing Ltd
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amino acid substitutions between ALF cases and controls.
Also, no significant differences by ANOVA were observed in
the Shannon entropy and genetic similarity between the ALF
case and control sequences among sub-genotype IA. The
mean nucleotide identity among ALF cases and control
sequences were 96.8 per 100 nucleotides (SD = 1.78) and
96.6% (SD = 1.81) among the sub-genotype IA (ANOVA,
P = 0.447; Table 2). However, similar analyses of the HAV
sub-genotype IB sequences showed a higher nucleotide and
amino acid identity among HAV variants from ALF cases
than controls (ANOVA, P < 0.01; Table 2). Rates of spon-
taneous survival were not significantly different between the
two sub-genotypes (chi-square test, Table 3).
PCR negative cases
The six PCR negative samples had viral loads below the
lower limit of detection of the assay of 0.1 plaque forming
units/100 lL [18]. PCR negative patients experienced worse
outcomes than those who were PCR positive (Table 3);
transplant free survival amongst PCR positive cases was
77.8% while PCR negative cases experienced a transplant
free survival of 16.7% (chi-square test, P < 0.01). Being PCR
positive was associated with a decreased risk of death or
transplant with an odds ratio of 0.057 (95% confidence
interval 0.005–0.641, P = 0.02). Of interest, the PCR neg-
ative cases as a group had lower mean peak ALT levels:
1414 IU/L compared to 3113 IU/L for the PCR positive ALF
patients. Prothrombin time/international normalized ratio
(INR) values were slightly more prolonged: 3.9 in the PCR
negative patients vs 2.9 for PCR positive cases.
HAV genotype IB
Four out of eighteen (22%) of the PCR positive ALF patients
were infected with sub-genotype IB, which is rare in the
United States. Though not identical, the sequences were
remarkably similar although the cases occurred over a three
and a half year period. None of the patients were born
abroad nor had they visited countries where genotype IB is
HAV genomic nucleotide sequences (nt101-7424)
1.0%
Nucleotide variation
ALF case-patients (N = 15)













































Figure 1 Genomic tree for 15 HAV ALF patients for whom adequate PCR products were available for sequencing, compared
with 28 control HAV patients without ALF. The mother and son who both developed acute liver failure after hepatitis A had
nearly identical viruses. The four patients from one site who were infected with sub-genotype IB were also remarkably similar
in sequence. Otherwise, there was no clustering of the HAV ALF cases. Number sequence of ALF patients = site number–
patient number–day of study.
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more common. During the same observation period (1998–
2004), only 19 (2.2%) sub-genotype IB cases were detected
in the United States among 834 hepatitis A cases identified
through different surveillance projects and this was also
highly significant (P < 0.01) by chi-square test.
Patient co-factors
Case report data revealed that 12 of 29 patients (41.4%)
reported having taken more than 1g of acetaminophen/day
for at least 3 days preceding hospital admission (Table 1),
therapeutic dosing that might indicate possible toxicity in the
setting of viral hepatitis. Four patients reported regular alco-
hol consumption (>2 drinks per night), one of whom also took
acetaminophen. There was no correlation between a history
of acetaminophen use and poorer outcomes. Acetaminophen
adducts were measured in all 24 for whom sera were avail-
able; 20 were undetectable and four demonstrated levels
below 1.0 nmol a-cys adducts/mL (range 0.18–0.34). None
were considered compatible with liver toxicity due to acet-
aminophen [16]. A more detailed clinical description of these
cases has been published recently. As in our prior report of the
same 29 cases, subject age, gender, and MELD score were not
predictive of patient outcomes [19].
DISCUSSION
Since prior studies had suggested a possible difference in viral
substitutions between HAV ALF patients and other patients
with acute HAV, we were interested in further exploring
whether unique viral genome patterns might predispose
hepatitis A patients to liver failure. We did not find a clear
difference in genomic sequences between patients with HAV
ALF and those with self-limited hepatitis A.
The rates of single nucleotide substitutions in the complete
HAV genome including both the 5¢ UTR and the VP1-P2B
regions showed no significant variation between those with
HAV ALF and patients with uncomplicated acute hepatitis A
infection. This finding suggests that variation in severity of
hepatitis A infection is not dependent upon rates of substi-
tution in the internal ribosomal entry site of the 5¢ UTR or
elsewhere in the genome. Furthermore, the differences in
rates of substitution in the transcribed amino acid residues
were also not significant in the two groups (Table 2).
Only a small fraction (8%) of acute HAV sera from a
previous large CDC cohort study was shown to be PCR
negative during the acute illness [12]. Among our HAV ALF
study patients, 25% (6/24) were PCR negative and this
status correlated with significantly worse outcomes defined
by a lower rate of spontaneous survival. The inability to
obtain PCR products in our study corresponds with an
undetectable or very low viral load. Low or undetectable
viral load at presentation has been previously cited as a
significant factor differentiating fulminant from non-ful-
minant cases for both hepatitis A [11] and hepatitis B [20].
Table 3 Outcomes by sub-genotype and by PCR status on
admission to study. Genotype was not associated with a
difference in outcome but early clearance, defined as PCR








Genotype 1B 3 (75%) 1 (25%) 0.88
Genotype 1A 11 (78.6%) 3 (21.4%)
PCR+ 14 (77.8%) 4 (22.2%) 0.007
PCR) 1 (16.7%) 5 (83.3%)
Table 2 Patients with HAV ALF and control HAV patients were compared for genetic complexity and identity. Sub-genotype


















IA Cases (n = 11) 0.0176 ±0.0593 0.0036 ±0.0261 96.8 ±1.78 99.4 ±0.21
Controls
(n = 20)
0.0170 ±0.0463 0.0037 ±0.0198 96.6 ±1.81 99.4 ±0.27
Sub-Total 0.0173 ±0.0532 0.0036 ±0.0231 96.6 ±1.80 99.4 ±0.25
IB Cases
(n = 4)
0.0045 ±0.0434** 0.0043 ±0.0419 99.5 ±0.12** 99.5 ±016**
Controls
(n = 8)
0.0228 ±0.0737 0.0057 ±0.0364 96.2 ±1.16 99.2 ±0.23
Sub-total 0.0137 ±0.0611 0.0049 ±0.0393 96.8 ±1.63 99.2 ±0.24
**P < 0.01.
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In vitro studies suggest that the immunologic response is
primarily responsible for the liver disease in HAV infections
[21]. In our study, undetectable viral load not only corre-
lated with more severe disease, but also indicated a worse
outcome amongst the ALF cases. However, the small num-
ber of patients with undetectable HAV RNA may limit the
generalizability of this finding. Quantitative PCR was not
available for this study.
With regard to use of acetaminophen, 12 of 29 patients
gave a history of acetaminophen ingestion of at least 1 g/
day for a minimum of 3 days (Table 1). We could not relate
a history of acetaminophen ingestion to poorer outcomes or
to more severe disease in this small case series, nor could we
identify other demographic or clinical factors such as age or
gender to be associated with poor outcome (Table 1).
Additional data were obtained on two clusters of HAV ALF
cases with highly conserved viral RNA genomes. The first
revealed a mother and son, both of whom presented with
HAV ALF within 1 month of each other to the same clinical
centre and without pre-existing liver disease. Although they
did not live together, they shared meals together during the
time of the first patients infection and the close genetic
similarity of their viruses confirms that infection appears to
have been transmitted from mother to son. HAV ALF cases
transmitted between family members have been reported in
the literature, specifically the occurrence of HAV ALF among
siblings [22,23]. Often the virus was transmitted to the
family via a community outbreak of routine HAV infections,
suggesting that host factors contributed to these more severe
outcomes. Furthermore, all reported inter-familial occur-
rences of HAV ALF have been among patients with no pre-
existing liver condition. In both previously reported studies
of siblings, the infections occurred in young patients whose
age ranged from 16 to 24 years. Genetic predisposition to a
fulminant course could be a factor considering the inter-
familial HAV ALF outbreak we observed in our study,
emphasizing the possible importance of the immunological
response to outcome.
A second cluster of HAV ALF cases came from a single
centre. Four of five cases from this site were sub-genotype
IB, which occurs very infrequently in the United States.
This finding coincides with epidemiological data from typ-
ical acute hepatitis A cases that suggest that community
reservoirs of infection may be present for long periods of
time under certain circumstances [12]. The near identity of
all four IB sequences, coupled with the rarity of genotype
IB, suggest ongoing transmission of this one strain within
the community and that it may be somewhat more viru-
lent than other subtypes but this remains highly specula-
tive.
Our study was limited in that we had serum samples on
only 24 of the 29 patients with HAV ALF in the study. In
addition, we could not perform phylogenetic analysis on five
of the six patients because they were PCR negative repeat-
edly during the study period. Finally, the case controls used
in this analysis of whole genome sequencing were not
obtained from the same local hospital as the ALF index case
due to the limited number of annual HAV cases that the CDC
has access to. Nonetheless, matching based upon medical
centre location and year of infection was undertaken. The
small number of cases in this study of acute liver failure
provides further evidence of the declining incidence of HAV
infection in the United States [19].
In conclusion, viral factors including substitution rate in
the entire genome do not seem to differ between HAV ALF
patients and those with uncomplicated hepatitis A infection
in North America. While this study is limited in the number
of cases presented, the rapidly declining rate of HAV and HAV
associated ALF make it unlikely that larger studies will be
possible in the future at least in the United States. However,
further analysis of genotype I should be performed, particu-
larly in locations where HAV is still endemic. An undetect-
able viral load at the onset of liver failure correlated in our
study with worse outcomes. HAV RNA testing by PCR, if it
were readily obtainable, might help determine prognosis but
should not be used to preclude referral and listing for trans-
plantation. The association of undetectable viral load with
poor outcome suggests a genetic predisposition to a exces-
sive host immune response contributes to the more severe
disease observed. This is further supported by the occurrence
of familial ALF case clustering. Whole genome sequence
analyses of patients with ALF of diverse aetiologies compared
to ethnically matched controls may prove useful in identify-
ing the genetic basis for differences in outcomes with
hepatotrophic viruses [24].
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